You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 27, 2024

SUGAMMADEX SODIUM - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for sugammadex sodium and what is the scope of patent protection?

Sugammadex sodium is the generic ingredient in two branded drugs marketed by Msd Sub Merck, Aspiro, and Zydus Pharms, and is included in three NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Sugammadex sodium has forty-two patent family members in thirty countries.

There are two drug master file entries for sugammadex sodium. Two suppliers are listed for this compound. There is one tentative approval for this compound.

Recent Clinical Trials for SUGAMMADEX SODIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Korea University Ansan HospitalPhase 4
YingHsuanTaiN/A
Zhejiang Cancer HospitalN/A

See all SUGAMMADEX SODIUM clinical trials

Generic filers with tentative approvals for SUGAMMADEX SODIUM
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up500MG/5ML(100MG/ML)INJECTABLE;INJECTION
⤷  Sign Up⤷  Sign Up200MG/2ML(100MG/ML)INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for SUGAMMADEX SODIUM
Paragraph IV (Patent) Challenges for SUGAMMADEX SODIUM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BRIDION Injection sugammadex sodium 200 mg/2 mL and 500 mg/5 mL 022225 14 2019-12-16

US Patents and Regulatory Information for SUGAMMADEX SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms SUGAMMADEX SODIUM sugammadex sodium SOLUTION;INTRAVENOUS 214290-001 Oct 4, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aspiro SUGAMMADEX SODIUM sugammadex sodium SOLUTION;INTRAVENOUS 214337-002 Jun 9, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 AP RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms SUGAMMADEX SODIUM sugammadex sodium SOLUTION;INTRAVENOUS 214290-002 Oct 4, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aspiro SUGAMMADEX SODIUM sugammadex sodium SOLUTION;INTRAVENOUS 214337-001 Jun 9, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SUGAMMADEX SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SUGAMMADEX SODIUM

Country Patent Number Title Estimated Expiration
Czech Republic 20021814 ⤷  Sign Up
Germany 60017947 ⤷  Sign Up
Slovakia 7262002 6-MERCAPTO-CYCLODEXTRIN DERIVATIVES: REVERSAL AGENTS FOR DRUG-INDUCED NEUROMUSCULAR BLOCK ⤷  Sign Up
Russian Federation 2260013 ПРОИЗВОДНЫЕ 6-МЕРКАПТОЦИКЛОДЕКСТРИНА: РЕВЕРСИРУЮЩИЕ АГЕНТЫ ДЛЯ ИНДУЦИРОВАННОЙ ЛЕКАРСТВЕННЫМ СРЕДСТВОМ НЕЙРОМЫШЕЧНОЙ БЛОКАДЫ (DERIVATIVES OF 6-MERCAPTOCYCLODEXTRIN: REVERSING AGENTS FOR DRUG- INDUCED NEUROMUSCULAR BLOCKADE) ⤷  Sign Up
Poland 356097 ⤷  Sign Up
Hong Kong 1049489 ⤷  Sign Up
Mexico PA02004940 DERIVADOS DE 6-MERCAPTO-CICLODEXTRIN: AGENTES DE REVERTIMIENTO PARA BLOQUEO NEUROMUSCULAR INDUCIDO POR FARMACOS. (6 MERCAPTO CYCLODEXTRIN DERIVATIVES: REVERSAL AGENTS FOR DRUG INDUCED NEUROMUSCULAR BLOCK.) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SUGAMMADEX SODIUM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1259550 2008C/047 Belgium ⤷  Sign Up PRODUCT NAME: SUGAMMADEX SODIQUE; AUTHORISATION NUMBER AND DATE: EU/1/08/466001 20080729
1259550 C01259550/01 Switzerland ⤷  Sign Up FUSION; FORMER OWNER: ORGANON BIO SCIENCES NEDERLAND B.V., NL
1259550 47/2008 Austria ⤷  Sign Up PRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTRAEGLICHES SALZ HIERVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
1259550 340 Finland ⤷  Sign Up
1259550 CA 2009 00002 Denmark ⤷  Sign Up PRODUCT NAME: SUGAMMADEX ELLER FARMACEUTISK AKTIVE SALTE ELLER ESTERE DERAF, HERUNDER SUGAMMADEXNATRIUM
1259550 SZ 47/2008 Austria ⤷  Sign Up PRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTRÄGLICHES SALZ HIERVON
1259550 122008000068 Germany ⤷  Sign Up PRODUCT NAME: SUGAMMADEX ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.